| Literature DB >> 23586671 |
Kumpei Tanisawa1, Eri Mikami, Noriyuki Fuku, Yoko Honda, Shuji Honda, Ikuro Ohsawa, Masafumi Ito, Shogo Endo, Kunio Ihara, Kinji Ohno, Yuki Kishimoto, Akihito Ishigami, Naoki Maruyama, Motoji Sawabe, Hiroyoshi Iseki, Yasushi Okazaki, Sanae Hasegawa-Ishii, Shiro Takei, Atsuyoshi Shimada, Masanori Hosokawa, Masayuki Mori, Keiichi Higuchi, Toshio Takeda, Mitsuru Higuchi, Masashi Tanaka.
Abstract
BACKGROUND: Senescence-accelerated mice (SAM) are a series of mouse strains originally derived from unexpected crosses between AKR/J and unknown mice, from which phenotypically distinct senescence-prone (SAMP) and -resistant (SAMR) inbred strains were subsequently established. Although SAMP strains have been widely used for aging research focusing on their short life spans and various age-related phenotypes, such as immune dysfunction, osteoporosis, and brain atrophy, the responsible gene mutations have not yet been fully elucidated.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23586671 PMCID: PMC3637625 DOI: 10.1186/1471-2164-14-248
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Number of mapped reads and read depth obtained through exome sequencing of 11 mouse strains
| Targeted exons | 221,784 | 221,784 | 221,784 | 221,784 | 221,784 | 221,784 | 221,784 | 221,784 | 221,784 | 221,784 | 221,784 | 221,784 |
| Target exons with no coverage | 7,740 | 7,132 | 6,945 | 7,004 | 7,238 | 6,867 | 6,924 | 6,332 | 7,165 | 7,557 | 7,384 | 7,117 |
| Total Target bases | 51,555,503 | 51,555,503 | 51,555,503 | 51,555,503 | 51,555,503 | 51,555,503 | 51,555,503 | 51,555,503 | 51,555,503 | 51,555,503 | 51,555,503 | 51,555,503 |
| Target bases not covered | 4,530,669 | 4,368,898 | 4,182,707 | 4,142,933 | 4,167,472 | 3,987,407 | 4,013,747 | 3,824,098 | 4,138,242 | 4,334,915 | 4,556,739 | 4,204,348 |
| Percent of target bases not covered | 8.8% | 8.5% | 8.1% | 8.0% | 8.1% | 7.7% | 7.8% | 7.4% | 8.0% | 8.4% | 8.8% | 8.2% |
| Total reads | 51,745,673 | 35,778,184 | 46,935,236 | 49,808,616 | 46,543,914 | 60,395,876 | 55,759,506 | 92,605,357 | 59,459,968 | 33,681,727 | 33,076,734 | 51,435,526 |
| Reads in target regions | 37,488,887 | 30,022,764 | 38,828,147 | 39,487,865 | 35,776,159 | 44,391,567 | 43,666,102 | 76,028,527 | 42,978,757 | 23,655,073 | 24,442,946 | 39,706,072 |
| Reads off target regions | 14,256,786 | 5,755,420 | 8,107,089 | 10,320,751 | 10,767,755 | 16,004,309 | 12,093,404 | 16,576,830 | 16,481,211 | 10,026,654 | 8,633,788 | 11,729,454 |
| Percent of reads in target regions | 72.4% | 83.9% | 82.7% | 79.3% | 76.9% | 73.5% | 78.3% | 82.1% | 72.3% | 70.2% | 73.9% | 76.9% |
| Coverage at 1× | 91.2% | 91.5% | 91.9% | 92.0% | 91.9% | 92.3% | 92.2% | 92.6% | 92.0% | 91.6% | 91.2% | 91.8% |
| Coverage at 5× | 83.0% | 81.6% | 84.4% | 85.2% | 84.8% | 86.6% | 86.5% | 89.0% | 86.3% | 80.5% | 79.9% | 84.4% |
| Coverage at 10× | 71.4% | 67.1% | 73.2% | 74.6% | 73.4% | 77.6% | 77.4% | 84.0% | 77.4% | 63.1% | 62.9% | 72.9% |
| Coverage at 20× | 49.6% | 41.6% | 50.9% | 52.9% | 50.0% | 57.6% | 57.2% | 72.3% | 57.6% | 34.6% | 35.1% | 50.9% |
| Average depth of coverage within target regions | 31.0× | 25.3× | 32.7× | 33.0× | 29.6× | 37.0× | 36.3× | 63.7× | 35.3× | 19.5× | 20.2× | 33.1× |
Number of SNVs identified through exome sequencing of 11 mouse strains
| Total SNVs | 112245 | 85198 | 90734 | 97039 | 106341 | 104290 | 108059 | 108880 | 121527 | 100463 | 3484 |
| Exonic SNVs | 35791 | 32019 | 32659 | 34048 | 35752 | 35817 | 36174 | 38432 | 38925 | 32816 | 1407 |
| Homozygous | 28916 | 26142 | 27914 | 26142 | 29282 | 29310 | 30253 | 25891 | 31338 | 26880 | 158 |
| Non-synonymous | 7364 | 6811 | 7106 | 7435 | 7429 | 7413 | 7588 | 6507 | 7843 | 6903 | 63 |
| Novel | 310 | 260 | 316 | 273 | 317 | 286 | 317 | 230 | 491 | 245 | 39 |
| Total MNVs | 2251 | 1610 | 1757 | 1870 | 2093 | 2007 | 2207 | 2210 | 2245 | 1834 | 67 |
| Exonic MNVs | 529 | 433 | 478 | 473 | 528 | 511 | 535 | 571 | 539 | 407 | 22 |
| Homozygous | 404 | 346 | 375 | 393 | 428 | 412 | 406 | 420 | 417 | 349 | 14 |
| Non-synonymous | 258 | 228 | 243 | 260 | 279 | 273 | 262 | 274 | 294 | 215 | 12 |
| Novel | 49 | 33 | 48 | 43 | 50 | 48 | 51 | 63 | 32 | 32 | 8 |
| Total Indels | 4439 | 3189 | 3653 | 3932 | 4446 | 4286 | 4749 | 4287 | 4943 | 3988 | 111 |
| Exonic Indels | 470 | 371 | 406 | 413 | 478 | 494 | 505 | 498 | 554 | 411 | 33 |
| Homozygous | 83 | 64 | 65 | 62 | 69 | 68 | 81 | 77 | 94 | 76 | 3 |
| Frameshift | 11 | 8 | 8 | 9 | 7 | 8 | 10 | 10 | 14 | 8 | 0 |
| Novel | 3 | 2 | 4 | 6 | 2 | 3 | 4 | 3 | 7 | 2 | 0 |
| Total Gain of Stops | 242 | 125 | 149 | 155 | 158 | 153 | 177 | 246 | 253 | 132 | 30 |
| Homozygous | 72 | 56 | 68 | 76 | 61 | 67 | 73 | 57 | 68 | 60 | 1 |
| Novel | 10 | 2 | 4 | 6 | 8 | 5 | 10 | 8 | 5 | 1 | 1 |
Missense SNVs detected among all of the SAMP strains, but absent in the SAMR and AKR/J strains
| Chr6:113283636 | 8-oxoguanine DNA-glycosylase 1 | c.1125C>T | p.R304W | 0 | 0.999 | NOD/ShLtJ | |
| Chr6:115509985 | tRNA splicing endonuclease 2 homolog (S. cerevisiae) | c.728C>T | p.P228L | 0.32 | 0* | 129P2/OlaHsd, 129S1/SvImJ, 129S5SvEvBrd, DBA/2J, LP/J, NOD/ShiLtJ, NZO/HlLtJ, WSB/EiJ | |
| Chr6:115799662 | methyl-CpG binding domain protein 4 | c.896C>T | p.D129N | 0.12 | 0.996 | 129P2/OlaHsd, 129S1/SvImJ, 129S5SvEvBrd, DBA/2J, LP/J, NOD/ShiLtJ, NZO/HlLtJ | |
| Chr6:116186163 | DNA segment, Chr 6, Wayne State University 116, expressed(WASH complex subunit FAM21) | c.1737C>T | p.P556S | 0.73 | 0.059* | 129P2/OlaHsd, 129S1/SvImJ, 129S5SvEvBrd, DBA/2J, LP/J, NOD/ShiLtJ, NZO/HlLtJ | |
| Chr6:116360826 | arachidonate 5-lipoxygenase | c.2040C>T | p.V646I | 0.07 | 0 | 129P2/OlaHsd, 129S1/SvImJ, 129S5SvEvBrd, DBA/2J, LP/J, NOD/ShiLtJ, NZO/HlLtJ | |
| Chr10:24020000 | monooxygenase, DBH-like 1 | c.1634G>A | p.R516K | 1 | 0* | NOD/ShiLtJ, WSB/EiJ | |
| Chr10:24021342 | monooxygenase, DBH-like 1 | c.1836A>C | p.K583N | 0.39 | 0.006 | NOD/ShiLtJ, WSB/EiJ |
*Human protein sequence is in conflict with the mouse sequence at the position indicated.
Top 5 overrepresented GO terms within the 6 genes including missense SNVs detected among all of the SAMP strains, but absent in the SAMR and AKR/J strains
| GO:0006284 | base-excision repair | 17 | 2 | 0.01 | 1.35×10-5 | 0.0003 | |
| GO:0006281 | DNA repair | 213 | 2 | 0.08 | 0.0022 | 0.0202 | |
| GO:0006950 | response to stress | 1107 | 3 | 0.39 | 0.0042 | 0.0202 | |
| GO:0034984 | cellular response to DNA damage stimulus | 243 | 2 | 0.09 | 0.0028 | 0.0202 | |
| GO:0006974 | response to DNA damage stimulus | 274 | 2 | 0.1 | 0.0036 | 0.0202 |
Novel deleterious mutations detected among multiple SAMP strains, but absent in the SAMR and AKR/J strains
| Chr14:35357289 | LIM domain binding 3 | c.1555G>A | p.R473W | SAMP1/SkuSlc,SAMP3/SlcIdr,SAMP6/TaSlc, SAMP10/TaSlc, SAMP11/SlcIdr | 0.02 | 0.968 | |
| Chr14:57654538 | gap junction protein, alpha 3 | c.1427A>G | p.S405P | SAMP3/SlcIdr,SAMP6/TaSlc, SAMP10/TaSlc, SAMP11/SlcIdr | 0.09 | 0.917† | |
| Chr7:28301176 | periaxin | c.784C>T | p.R167C | SAMP3/SlcIdr, SAMP10/TaSlc, SAMP11/SlcIdr | 0.01 | 0.998 | |
| Chr11:49958661 | TBC1 domain family, member 9B | c.560T>C | p.S161P | SAMP3/SlcIdr, SAMP10/TaSlc | 0 | 0.867 | |
| Chr11:70277672 | zinc finger, MYND-type containing 15 | c.1859C>T | p.T461M | SAMP3/SlcIdr, SAMP10/TaSlc | 0.05 | N.A. | |
| Chr18:37455608 | protocadherin beta 2 | c.1115G>A | p.G327R | SAMP10/TaSlc, SAMP11/SlcIdr | 0 | N.A. | |
| Chr18:37495244 | protocadherin beta 6 | c.1563G>T | p.E521D | SAMP10/TaSlc, SAMP11/SlcIdr | 0 | N.A. |
†Human protein sequence is in conflict with the mouse sequence at the position indicated.
Novel deleterious mutations specific to SAMP6/TaSlc
| Chr2:29947531 | zinc finger, DHHC domain containing 12 | c.381G>A | p.R112C | 0 | 0.999 | |
| Chr2:31793494 | laminin gamma 3 | c.4202A>G | p.D1380G | 0.05 | 0.399 | |
| Chr7:132719753 | interleukin 4 receptor, alpha | c.1860delC | p.S540fs | N.A. | N.A. | |
| Chr10:79474903 | ATP-binding cassette, sub-family A (ABC1), member 7 | c.5477G>A | p.R1826H | 0.01 | 0.108 | |
| Chr15:99998371 | DIP2 disco-interacting protein 2 homolog B | c.1708G>A | p.A544T | 0.05 | 0.17 | |
| Chr17:25257897 | pentraxin 4 | c.176A>T | p.R34S | 0* | 0.999 | |
| Chr19:4153338 | coronin, actin-binding protein 1B | c.1253C>T | p.R393W | 0 | 0.998 |
*The score is low confidence because the prediction was based on sequences too closely related.
Novel deleterious mutations specific to SAMP8/TaSlc
| Chr2:60190230 | lymphocyte antigen 75 | c.1657G>A | p.R553W | 0.02 | 0.997 | |
| Chr5:75023400 | ligand of numb-protein X 1 | c.685T>A | p.N154Y | 0 | 0.318 | |
| Chr15:34358663 | matrilin 2 | c.2668C>T | p.A806V | 0.01 | 0.717 | |
| Chr16:14195230 | myosin, heavy polypeptide 11, smooth muscle | c.5938C>T | p.R1945H | 0.17 | 0.99 | |
| Chr16:17506416 | apoptosis-inducing factor, mitochondrion-associated 3 | c.1966G>T | p.K582N | 0.01 | 0.879 |
Figure 1Multiple sequence alignment of periaxin. The multiple sequence alignment of periaxin is displayed. The nuclear localization signal of periaxin (amino acids 118–196) comprises 3 highly basic sub-domains. The p.R167C mutation is located in the second sub-domain (amino acid sequence KFSRLRRGLKAEAVK).
Figure 2Visualization of short read mapping on the Avadis NGS genome browser. (a) The Il4ra c.1860delC mutation identified in SAMP6/TaSlc is visualized on the Avadis NGS genome browser. The reference genome sequence GRCm38 (NCBI37/mm9) is shown above, and short DNA reads are aligned to this reference sequence. Hyphens on the reads mean nucleotide deletion at that position. (b) Sanger sequencing chromatogram of the Il4ra gene is displayed. The Il4ra c.1860delC mutation in SAMP6/TaSlc was confirmed by Sanger sequencing.
Figure 3Summary of candidate mutations regulating various pathogenic phenotypes in SAMP strains. Described mutations except for Ogg1 p.R304W and Mbd4 p.D129N are SAMP-specific novel non-synonymous mutations that were identified in the present study. Although Ogg1 p.R304W and Mbd4 p.D129N were detected in other strains, they would be involved in the susceptibility of diseases via defects in DNA repair.